AEON Biopharma(AEON) - 2024 Q4 - Annual Results

Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Fourth Quarter 2024 and Full Year Financial Results and Provides Corporate Update – Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – IRV ...